These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20189109)

  • 1. Affinity reagents that target a specific inactive form of protein kinases.
    Ranjitkar P; Brock AM; Maly DJ
    Chem Biol; 2010 Feb; 17(2):195-206. PubMed ID: 20189109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affinity purification of protein kinases that adopt a specific inactive conformation.
    Ranjitkar P; Maly DJ
    Methods Mol Biol; 2012; 928():143-51. PubMed ID: 22956139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
    Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
    Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence determinants of a specific inactive protein kinase conformation.
    Hari SB; Merritt EA; Maly DJ
    Chem Biol; 2013 Jun; 20(6):806-15. PubMed ID: 23790491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors.
    Messoussi A; Peyronnet L; Feneyrolles C; Chevé G; Bougrin K; Yasri A
    Molecules; 2014 Oct; 19(10):16223-39. PubMed ID: 25310149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
    Modi SJ; Kulkarni VM
    J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ABC of protein kinase conformations.
    Möbitz H
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1555-66. PubMed ID: 25839999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining the Protein Kinase Conformational Space with Machine Learning.
    Ung PM; Rahman R; Schlessinger A
    Cell Chem Biol; 2018 Jul; 25(7):916-924.e2. PubMed ID: 29861272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
    Ung PM; Schlessinger A
    ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
    Simard JR; Rauh D
    Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
    Zhao Z; Wu H; Wang L; Liu Y; Knapp S; Liu Q; Gray NS
    ACS Chem Biol; 2014 Jun; 9(6):1230-41. PubMed ID: 24730530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
    Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
    ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Protein Kinase-Ligand Interactions through 2.5D Kinochemometrics.
    Bosc N; Wroblowski B; Meyer C; Bonnet P
    J Chem Inf Model; 2017 Jan; 57(1):93-101. PubMed ID: 27983837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining a new nomenclature for the structures of active and inactive kinases.
    Modi V; Dunbrack RL
    Proc Natl Acad Sci U S A; 2019 Apr; 116(14):6818-6827. PubMed ID: 30867294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.
    Ramakrishnan C; Mary Thangakani A; Velmurugan D; Anantha Krishnan D; Sekijima M; Akiyama Y; Gromiha MM
    J Biomol Struct Dyn; 2018 May; 36(6):1566-1576. PubMed ID: 28589758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.